Bordeaux

• Efficacy of intravesical oxybutynin in children with neurogenic bladder dysfunction: A randomized, prospective controlled multi-center trial … Recruiting
  2022-501902-36-00 5 2026-01-15 spina bifida
• An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with S … Recruiting
  2024-520208-25-00 4 2026-01-15 Still’s disease
• NEOREM/NEO-1 - NEOREM: Neo-adjuvant Immunotherapy Master Trial for Localized Cancers / NEO-1: Neo-adjuvant immunotherapy in patients with l … Recruiting
  2025-522127-95-00 4 2026-01-12 NEOREM: Localized solid malignancies that are eligible to receive neo-
• Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting
  2022-501562-22-01 4 2026-01-05 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• Study to Assess the Injection Burden, Safety, Efficacy, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) … Recruiting
  2024-512298-28-00 11 2025-12-18 Neovascular age-related macular degeneration
• Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis Recruiting
  2024-518288-37-00 3 2025-12-18 Lupus Nephritis
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting
  2024-517653-27-00 4 2025-12-17 Prostate Cancer
• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting
  2025-520825-19-00 5 2025-12-16 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Ber
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting
  2025-522860-34-00 5 2025-12-16 Chronic lymphocytic leukemia (CLL)
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma Recruiting
  2024-513619-28-00 1 2025-12-11 Clear Cell Renal Cell Carcinoma
• PHASE 2B TRIAL OF AEF0217 IN PARTICIPANTS WITH DOWN SYNDROME Recruiting
  2025-521013-10-00 4 2025-12-11 Treatment of behavioural and cognitive impairments in Down syndrome.
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 Recruiting
  2024-514763-25-01 1 2025-12-04 spinocerebellar ataxia type 2
• RHIBOT II - Medium- and long-term efficacy of two ultrasound-guided intra-articular injections of onabotulinumtoxinA (Botox®) combined with … Recruiting
  2024-515028-35-00 5 2025-12-03 Adults aged at least 18 years with painful base-of-thumb osteoarthriti
• Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting
  2024-519971-25-00 5 2025-12-03 Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting
  2024-519727-18-00 1 2025-11-25 Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer
• Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-520927-26-00 5 2025-11-24 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• RLY-2608-201-Ph2 Study of RLY-2608 in PROS and PIK3CA Driven Malformations Recruiting
  2024-518895-30-00 4 2025-11-21 PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA
• TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II t … Recruiting
  2023-510568-11-00 9 2025-11-18 High grade brain tumors
• A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting
  2024-512849-17-00 5 2025-11-14 Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)

Showing 241–264 of 1,096 trials